














Spring Creek Capital Corporation: Spring Creek Capital Announces Logistics Agreement Between Stratis Healthcare, Inc. and Thera
Published in Business and Finance on Tuesday, July 21st 2009 at 10:38 GMT, Last Modified on 2009-07-21 10:39:03 by Market Wire

MERRITT ISLAND, FL--(Marketwire - July 21, 2009) - Spring Creek Capital Corp. (
TheraBiogen is the exclusive North American manufacturer and distributor of homeopathic nasal spay cold, flu and allergy relief products which contain no zinc, and which are distributed under the TheraMax™ trade name. The TheraMax™ products are being introduced to the marketplace in the second half of 2009 through a number of pharmaceutical distributors and retailers. The TheraMax™ products are proven to provide fast, effective relief for sufferers of colds, flus and allergies in a short period of time. They are formulated to avoid previously known health side effects as stated by the FDA such as those caused by zinc-based products.
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in Spring Creek Capital's most recently filed Form 10-K and Form 10-Q reports. The forward-looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. Spring Creek Capital assumes no obligation to update the statements contained in this release.